Prana Biotechnology Ltd has received ethics committee approval and has commenced recruitment for its phase I clinical trial evaluating the safety, tolerability and pharmacokinetics of the company's lead drug candidate, PBT434, in healthy volunteers.
Original Article: Prana to initiate phase 1 trial of PBT434 to treat Parkinsonian diseases